Drug Trial Radar · NCT05957367
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Sep 28, 2023
Primary completion
Mar 2027
Study completion Mar 2029
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
Conditions
- GIST
Interventions
InlexisertibDrug
Oral Tablet Formulation
RipretinibDrug
Oral Tablet Formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (Escalation Phase)Time frame: Approximately 24 months
- Recommended Phase 2 Doses (RP2D) (Escalation Phase)Time frame: Approximately 18 months
- Objective response rate (ORR) (Expansion Phase)Time frame: Approximately 24 months
Locations
28 sites in 9 countries. Site status is shown where the registry gives one.
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, California
Sylvester Comprehensive Cancer Center
Miami, Florida
University of Massachusetts Worcester
Worcester, Massachusetts
START Midwest
Grand Rapids, Michigan
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Virginia Cancer Specialist, PC
Fairfax, Virginia
Aarhus University Hospital
Aarhus, Denmark
Centre Oscar Lambret
Lille, France
Institut Curie, Service d'Oncologie Médicale
Paris, France
Hôpital Européen Georges Pompidou
Paris, France
Universitatsklinikum Franfurt
Frankfurt, Germany
Universitätsklinikum Eppendorf
Hamburg, Germany
AOU Careggi - Padiglione 16 - Piano Terra - Ambulatori Oncologici - Ufficio Trial
Florence, Italy
IRCCS Azienda Ospedaliera Metropolitana
Genova, Italy
Istituto Europeo di Oncologia
Milan, Italy
Antonie Van Leeuwenhoek Hospital
Amsterdam, Netherlands
Radboudumc
Nijmegen, Netherlands
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E.
Porto, Portugal
ICO Hospitalet
Barcelona, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario Clinico San Carlos
Madrid, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
Inselspital Universitätsklinikum Bern
Bern, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.